Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine in pediatric schizophrenia, bipolar I disorder, and autism spectrum disorder
NCT04578756Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2021
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of cariprazine in schizophrenia, bipolar I disorder, Autism Spectrum Disorder (ASD), sponsored by AbbVie Inc.. Started Feb 2021; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophreniabipolar I disorderAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04578756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578756.